Selecting COVID-19 convalescent plasma for neutralizing antibody potency using a high-capacity SARS-CoV-2 antibody assay.
Erin Goodhue MeyerGraham SimmonsEduard GrebeMichael GannettSergej FranzOrsolya DarstClara Di GermanioMars StonePaul ContestableAlicia PrichardRita ReikRalph R VassalloPampee P YoungMichael P BuschPhillip WilliamsonLarry J DumontPublished in: Transfusion (2021)
Selection of a clinically effective nAb titer will impact availability of CCP. Product release with CoV2T assay S/Co criterion must balance the risk of releasing products below target nAb titers with the cost of false negatives. A two-step testing scheme may be optimal, with nAb testing on CoV2T samples with S/Cos below criterion.